Given a series of high-profile disappointments, most recently that of Dendreon Corp.’s prostate cancer drug Provenge (sipuleucel-T), Big Pharma has been understandably hesitant to commit significant resources to potentially promising cell and gene therapies.
Economic and technological hurdles and, perhaps most important, lack of proven efficacy have until now made these and other “advanced...